Navigation

Acute coronary syndrome - rivaroxaban [ID532]

Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome

Status: In development
Expected date of issue: March 2015
Referral date: May 2012
Process: STA
Notes:

Scoped as part of Batch 22

Topic area:
  • Cardiovascular
 

NICE project team

Executive Lead: TBC
Technical Lead: TBC
Communications manager: Phil Ranson
Project manager: TBC
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: 24 September 2014
2nd appraisal committee meeting 25 November 2014
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Notes
18 April 2013

The manufacturer does not have the necessary information to provide their submission in time for a Committee discussion to take place on 8th May 2013. Therefore the first Committee discussion will not take place on 8th May 2013.

15 November 2012

This appraisal has been rescheduled. This is to allow the manufacturer to access the information they require for their submission.

The first Committee discussion will now take place on 8 May 2013. The second Committee discussion if required will take place on 9 July 2013.

Top


 

Key documents

This page was last updated: 04 July 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.